for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
  The Medical Letter
  [SJR: 0.161]   [H-I: 15]   [8 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 0025-732X - ISSN (Online) 1523-2859
   Published by The Medical Letter, Inc Homepage  [1 journal]
  • An Inhaled Insulin (Afrezza) - The Medical Letter
    • Authors: admin
      Abstract: March 2, 2015 - The FDA has approved an inhaled, rapid-acting, dry-powder formulation of recombinant human insulin (Afrezza – Mannkind/Sanofi) for treatment of adults with type 1 or type 2 diabetes. In patients with type 1 diabetes, the drug must be used in combination with long-acting insulin. Another inhaled, rapid-acting insulin (Exubera) was approved in 2006 for the same indication, but was withdrawn from the market the following year.
       
  • Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic - The
           Medical Letter
    • Authors: admin
      Abstract: March 2, 2015 - The FDA has approved ceftolozane/tazobactam (Zerbaxa – Cubist), a combination of a new cephalosporin antibiotic and a beta-lactamase inhibitor, for intravenous treatment of complicated urinary tract and intra-abdominal infections in adults.
       
  • Correction: Secondary Prevention of Stroke - The Medical Letter
    • Authors: admin
      Abstract: March 2, 2015 - In the article on Secondary Prevention of Stroke in the December 8, 2014 issue of The Medical Letter (volume 56, page 125), the duration of treatment with clopidogrel plus aspirin in patients who have had a stroke or TIA should be limited to 21 days, not 90 days. This error, which appears twice, in the paragraphs titled "Clopidogrel Plus Aspirin" and "Conclusion", has been corrected in the article as it appears online.
       
  • Tavaborole Topical Solution (Kerydin) for Onychomycosis - The Medical
           Letter
    • Authors: admin
      Abstract: March 2, 2015 - The FDA has approved tavaborole 5% solution (Kerydin – Anacor Pharmaceuticals) for topical treatment of toenail onychomycosis due to Trichophyton rubrum or Trichophyton mentagrophytes. It is the first oxaborole antifungal drug to be approved for this indication.
       
  • Suvorexant (Belsomra) for Insomnia - The Medical Letter
    • Authors: admin
      Abstract: March 2, 2015 - The FDA has approved suvorexant (Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.
       
  • Adult Immunization - Treatment Guidelines
    • Authors: admin
      Abstract: June 1, 2014 - Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately.
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014